Remove Drug Trials Remove Drugs Remove Trials
article thumbnail

Alnylam details anticipated results from heart disease drug trial

Bio Pharma Dive

Fuller data from Alnylam’s APOLLO-B trial confirm the success reported by the company last month, but won’t end a debate on the degree of benefit offered by its drug.

article thumbnail

Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

Bio Pharma Dive

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen to test new way to lower heart risk with large drug trial

Bio Pharma Dive

Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).

article thumbnail

Alnylam change to heart drug trial sparks doubts, sinking shares

Bio Pharma Dive

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

article thumbnail

EyePoint sees stock surge on AMD drug trial data

Bio Pharma Dive

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

article thumbnail

JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

Bio Pharma Dive

Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial.

Trials 298
article thumbnail

Alexion discontinues ALS drug trial due to 'lack of efficacy'

Bio Pharma Dive

The decision, which follows the recommendation of a data monitoring committee, is yet another setback in the search for more treatments for the neurological disease.